{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:04Z","timestamp":1786119544495,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Mavacamten is an innovative drug for hypertrophic obstructive cardiomyopathy (HOCM). It improves cardiac function by reducing left ventricular outflow tract obstruction. However, safety data in patients with liver and kidney impairment are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 68-year-old man was admitted with a history of HOCM, heart failure, gout, and chronic kidney and liver impairment. He was admitted because of worsening heart failure symptoms and an episode of upper gastrointestinal bleeding. The combined burden of these illnesses significantly impaired his ability to perform daily activities independently, leading to hospitalization for optimized management of his advanced cardiac disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Hypertrophic obstructive cardiomyopathy (apical aneurysm, post-cardiac resynchronization therapy), New York Heart Association class III. Hepatic schistosomiasis with portal hypertension, splenomegaly, upper GI bleeding, moderate anemia. Chronic gout with tophaceous deposits. Chronic kidney disease stage IIIb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Initiated mavacamten 2.5\u2009mg once daily for severe left ventricular outflow tract obstruction refractory to maximally tolerated beta-blockers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient showed significant improvement after treatment. The New York Heart Association class decreased from III to I-II, and the LVOTG dropped from 105 to 16\u2009mm Hg. Meanwhile, liver and kidney functions remained stable during the course of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case highlights the complexity of managing HOCM with multiorgan comorbidities, emphasizing the role of novel therapies (e.g., mavacamten) in refractory outflow obstruction and the need for tailored multidisciplinary approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046935","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:00:53Z","timestamp":1767711653000},"page":"e46935","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities: A case report"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-0330","authenticated-orcid":false,"given":"Liping","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8276-1650","authenticated-orcid":false,"given":"Fengqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ultrasound Medicine, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5708-4321","authenticated-orcid":false,"given":"Sophia","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Biology, Texas A&M University College of Arts and Science, College Station, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8390-806X","authenticated-orcid":false,"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ultrasound Medicine, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"R2-20260218","doi-asserted-by":"crossref","first-page":"91","DOI":"10.17925\/HI.2022.16.2.91","article-title":"Mavacamten: a first-in-class oral modulator of cardiac myosin for the treatment of symptomatic hypertrophic obstructive cardiomyopathy.","volume":"16","author":"Reyes","year":"2022","journal-title":"Heart Int"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy.","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"102430","DOI":"10.1016\/j.jaccas.2024.102430","article-title":"Usefulness of mavacamten in the challenging association of aortic stenosis and obstructive hypertrophic cardiomyopathy.","volume":"29","author":"Vanhaecke","year":"2024","journal-title":"JACC Case Rep"},{"key":"R5-20260218","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacemten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a ransomised, double-blind, placebo-controlled, phase 3 trial.","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 Results from the VALOR-HCM randomized clinical trial.","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"R7-20260218","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial.","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"R8-20260218","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/cpdd.1332","article-title":"Effects of omeprazole and verapamil on the pharmacokinetics, safety, and tolerability of mavacamten: two drug-drug interaction studies in healthy participants.","volume":"12","author":"Perera","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R9-20260218","doi-asserted-by":"crossref","first-page":"17428","DOI":"10.12677\/ACM.2023.13112441","article-title":"Research progress in the treatment of portal hypertensive gastropathy.","volume":"13","author":"Yintao","year":"2023","journal-title":"Adv Clin Med"},{"key":"R10-20260218","first-page":"1823","article-title":"2016 Chinese gout diagnosis and treatment guidelines.","volume":"39","author":"Xiaofeng","year":"2017","journal-title":"Zhejiang Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:28Z","timestamp":1786041208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046935","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-07-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}